We knew this day was coming it was just a matter of time. This morning Johnson and Johnson (NYSE: JNJ) released fourth quarter and full year results and for all practical purposes this once powerful company is no longer in diabetes. Yes, they still have Invokana but when it comes to diabetes devices the area where they used to shin darkness has set in. The decision has been made to shut down Animas with their patients shipped off to the evil empire and LifeScan is about to get new owners.
For those who are new to this wacky world this . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.